Alphabet (GOOGL) Deepens AI Spending While Maintaining Payouts: Is Its Capital Allocation Playbook Changing?

Alphabet Inc. Class A

Alphabet Inc. Class A

GOOGL

0.00

  • In late July 2026, Alphabet reported second-quarter 2026 results showing higher sales and net income alongside an affirmation of its US$0.22 quarterly dividend, while also filing a US$69.24 billion shelf registration for up to 200 million Class C shares tied to employee stock plans.
  • At the same time, Alphabet signaled an unprecedented AI and data center buildout, with capital expenditure guidance and long-term contractual obligations in the hundreds of billions of dollars, marking a sharp shift in how it deploys cash and manages future capacity.
  • We’ll now examine how Alphabet’s aggressive AI and data center capital expenditure escalation may reshape the company’s previously balanced investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Alphabet Investment Narrative Recap

To own Alphabet today, you need to believe its AI driven growth in Search, YouTube and Cloud can justify an enormous ramp in capital spending. The immediate catalyst is whether this AI infrastructure buildout translates into sustained revenue and operating income growth without permanently depressing free cash flow. The biggest risk now is that hundreds of billions in AI and data center commitments outstrip monetization; the recent news materially intensifies that concern.

The most relevant update is Alphabet’s Q2 2026 capital expenditure guidance, which now points to around US$195 billion to US$205 billion of spend this year and US$811 billion in long term contractual obligations. This scale of investment directly intersects with the AI and Cloud catalysts that previously rested on a more balanced capex profile, and it now sits alongside ongoing regulatory pressure and heavy Other Bets spending as a key factor investors need to track.

Yet behind the headline growth story, a more cautious view highlights that surging AI capex could compress margins and earnings in ways investors should be aware of...

Alphabet's narrative projects $701.1 billion revenue and $221.8 billion earnings by 2029. This requires 18.4% yearly revenue growth and about $61.6 billion earnings increase from $160.2 billion today.

Uncover how Alphabet's forecasts yield a $427.89 fair value, a 34% upside to its current price.

Exploring Other Perspectives

GOOGL 1-Year Stock Price Chart
GOOGL 1-Year Stock Price Chart

Some of the lowest ranked analysts were already assuming Alphabet’s earnings would fall from about US$244.1 billion to US$170.1 billion by 2029, so this latest capex surge may strengthen their argument that rising AI infrastructure costs and regulatory pressure could cap profits even if revenue keeps growing.

Explore 85 other fair value estimates on Alphabet - why the stock might be worth 28% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Alphabet research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Alphabet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alphabet's overall financial health at a glance.

No Opportunity In Alphabet?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

  • Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
  • The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
  • AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.